ADRN-12/LEADS (Longitudinal Endotyping of Atopic Dermatitis Through Transcriptomic Skin Analysis)
Trial Objectives
.jpg?width=383&height=218)
Eczema (atopic dermatitis) is typically classified as mild, moderate or severe. In this trial, researchers are studying gene expression for the varying severity levels of eczema in order to guide new and improved treatments strategies and more personalized treatments. Skin samples from participants will be collected using a specialized, noninvasive dermatologic skin tape. People with and without eczema are needed for this trial.
Who Can Participate
Adults ages 18 and older and kids ages 6 to 17 with and without eczema.
Age: 6-65 Gender: Any
Estimated Time Commitment
7-8 clinic visits over five to six months.
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Available
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
National Institutes of Health
Principal Investigators
-
Mark Boguniewicz, MD
-
Donald Y M Leung, MD, PhD